论文部分内容阅读
目的:探讨重组人脑利钠(rhBNP)联合左西孟旦治疗急性失代偿性心力衰竭患者的临床疗效及安全性。方法:将2015年1月-2016年1月我院收治的急性失代偿性心力衰竭患者83例随机分为对照组(n=41)和观察组(n=42),对照组行rhBNP治疗,观察组采用rhBNP联合左西孟旦治疗,比较两组治疗后的临床疗效及安全性。结果:两组治疗后的NT-ProBNP水平均低于治疗前,LVEF水平均高于治疗前,且观察组治疗后的NTProBNP水平低于对照组同期,LVEF水平高于对照组同期(P<0.05),两组治疗前后的LVEDD水平无明显差异。观察组和对照组治疗后的临床总有效率无明显差异(95.2%vs 87.8%,P>0.05);但观察组治疗后临床疗效优于对照组(P<0.05)。两组安全性指标无明显差异(P>0.05)。结论:rhBNP联合左西孟旦治疗急性失代偿性心力衰竭可明显提高治疗效果,且安全性高。
Objective: To investigate the clinical efficacy and safety of recombinant human brain natriuretic peptide (rhBNP) combined with levosimendan in patients with acute decompensated heart failure. Methods: 83 patients with acute decompensated heart failure admitted to our hospital from January 2015 to January 2016 were randomly divided into control group (n = 41) and observation group (n = 42), and rhBNP , The observation group with rhBNP combined with levosimendan treatment, the clinical efficacy and safety of the two groups were compared. Results: The levels of NT-ProBNP after treatment in both groups were lower than those before treatment, and the levels of LVEF were higher than those before treatment. The levels of NTProBNP in the observation group were lower than those in the control group and LVEF levels were higher than those in the control group (P <0.05) ), There was no significant difference between the two groups before and after treatment of LVEDD levels. There was no significant difference between the observation group and the control group (95.2% vs 87.8%, P> 0.05). However, the clinical efficacy of the observation group was better than that of the control group (P <0.05). No significant difference in safety indicators between the two groups (P> 0.05). Conclusion: rhBNP combined with levosimendan in the treatment of acute decompensated heart failure can significantly improve the therapeutic effect and is safe.